GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ANGLE PLC (OTCPK:ANPCY) » Definitions » EBITDA Margin %

ANGLE (ANPCY) EBITDA Margin % : -706.23% (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is ANGLE EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ANGLE's EBITDA for the six months ended in Jun. 2024 was $-9.29 Mil. ANGLE's Revenue for the six months ended in Jun. 2024 was $1.32 Mil. Therefore, ANGLE's EBITDA margin for the quarter that ended in Jun. 2024 was -706.23%.


ANGLE EBITDA Margin % Historical Data

The historical data trend for ANGLE's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANGLE EBITDA Margin % Chart

ANGLE Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,444.73 -1,605.86 -1,551.82 -2,040.93 -869.14

ANGLE Semi-Annual Data
Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,231.40 -1,911.87 -800.13 -952.67 -706.23

Competitive Comparison of ANGLE's EBITDA Margin %

For the Diagnostics & Research subindustry, ANGLE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANGLE's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ANGLE's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ANGLE's EBITDA Margin % falls into.



ANGLE EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ANGLE's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-24.049/2.767
=-869.14 %

ANGLE's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-9.294/1.316
=-706.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ANGLE  (OTCPK:ANPCY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


ANGLE EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ANGLE's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ANGLE Business Description

Traded in Other Exchanges
Address
10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
ANGLE PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.

ANGLE Headlines

From GuruFocus

Angle PLC Announces Holding(s) in Company - (1)

By ACCESSWIRE ACCESSWIRE 07-08-2020

Half Year 2023 Angle PLC Earnings Call Transcript

By GuruFocus Research 02-12-2024

Angle PLC Announces Exercise of Options and Total Voting Rights

By ACCESSWIRE ACCESSWIRE 04-30-2021

Angle PLC Announces Holding(s) in Company - (2)

By ACCESSWIRE ACCESSWIRE 07-08-2020

Half Year 2024 Angle PLC Earnings Call Transcript

By GuruFocus Research 09-27-2024

Half Year 2021 Angle PLC Earnings Call Transcript

By GuruFocus Research 02-12-2024

Angle PLC Announces AACR 2019

By ACCESSWIRE AccessWire 04-12-2019

Half Year 2020 Angle PLC Earnings Call Transcript

By GuruFocus Research 02-12-2024